CN104725480A - Signal transduction and transcriptional activation factor inhibitory polypeptide and application thereof - Google Patents
Signal transduction and transcriptional activation factor inhibitory polypeptide and application thereof Download PDFInfo
- Publication number
- CN104725480A CN104725480A CN201510157200.2A CN201510157200A CN104725480A CN 104725480 A CN104725480 A CN 104725480A CN 201510157200 A CN201510157200 A CN 201510157200A CN 104725480 A CN104725480 A CN 104725480A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- transcription factor
- intracellular signaling
- activating transcription
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the field of medicines, and in particular relates to a polypeptide provided with an inhibiting signal transduction and transcriptional activation factor and used for preventing and treating cancer recurrence and metastasis after breast cancer. The sequence of the polypeptide is MEQFRHLRANPSWPHLQMFP and is a brand-new sequence, the sequence can be used for in vitro inhibiting proliferation and migration of breast cancer cell, the survival rate of the tumor-bearing mice is improved in an in vivo test, and the polypeptide has potential new medicine development value.
Description
Technical field
The present invention relates to intracellular signaling and activating transcription factor and suppress polypeptide and application thereof, be specifically related to have and suppress intracellular signaling and activating transcription factor, the recurrence of prevention and therapy Mammary cancer cancer and the polypeptide of transfer.
Background technology
Female mammary gland is made up of skin, fibrous tissue, corpus mamma and fat, and mammary cancer is the malignant tumour occurring in mammary gland glandular epithelium tissue.In mammary cancer, 99% occurs in women, and the male sex only accounts for 1%.Current mammary cancer has become the able-bodied kinds of tumor of threat women.
Mammary gland is not the vitals maintaining human life activity, and breast cancer in situ is not fatal; But because breast cancer cell loses Normocellular characteristic, connect loose between cell, easily come off.Cancer cells is once come off, and free cancer cells can send out whole body with blood or lymph liquid, forms transfer, threat to life.How eliminating the distant metastasis of certain cancer or prevent recurrence, is indispensable integral part in cancer treatment method, is also the treatment mammary cancer hot issue inquired at present.
Intracellular signaling and activating transcription factor (STAT) are a kind of important nuclear factors.Activate JAK after cytokine and receptors bind, then activate STAT further.Research finds, STAT3 is unconventionality expression and activation in kinds of tumors tissue, and closely related with the propagation of tumour, differentiation, apoptosis, vasculogenesis, infiltration metastasis and immune evasion.The activity form of STAT3 albumen plays an important role in the Infiltration and metastasis process of kinds of tumors.Therefore, suppress intracellular signaling and activating transcription factor, the combination of intracellular signaling and activating transcription factor and VEGFR3 can be suppressed, suppress ripe lymphatic vessel to be formed, thus suppress the transfer of breast cancer cell, can the recurrence of prevention and therapy Mammary cancer cancer and transfer.
At present, the intracellular signaling of ripe exploitation and activating transcription factor is not had to suppress polypeptide to come out, for recurrence and the transfer of prevention and therapy Mammary cancer cancer.
Summary of the invention
goal of the invention
The invention provides brand-new sequence, this sequence is intracellular signaling and activating transcription factor antagonist, has good curative effect to mammary cancer.
technical scheme
intracellular signaling and activating transcription factor suppress polypeptide, it is characterized in that its sequence is MEQFRHLRANPSWPHLQMFP.
Intracellular signaling and activating transcription factor suppress the application of polypeptide in the recurrence and diversion medicaments of prevention and therapy Mammary cancer cancer.
beneficial effect
Utilize solid-phase synthesis chemosynthesis intracellular signaling and activating transcription factor to suppress polypeptide, this polypeptide has brand-new sequence, and this polypeptide can vitro inhibition intracellular signaling and activating transcription factor, the recurrence of prevention and therapy Mammary cancer cancer and transfer.The intracellular signaling that we find and activating transcription factor suppress polypeptide can suppress Cells Proliferation of Human Breast Cancer vigor simultaneously, and improve tumor-bearing mice survival rate in testing in vivo, have potential new drug development value.
Embodiment
Embodiment 1
Intracellular signaling and activating transcription factor suppress the effect of polypeptide breast cancer cell MCF-7 migration.
Adopt scratch experiment.First use marker pen at 24 orifice plates behind, compare with ruler, evenly must draw horizontal line, approximately every 0.5 ~ 1cm together, cross via hole.Every hole is through 3 lines; By becoming the MCF-7 cell of logarithmic growth, with 1.0 × 10
5add in 24 well culture plates, cultivate 24h.Within second day, compare ruler with 10 μ l rifle heads, perpendicular to horizontal line cut behind, with the point of crossing of cut and horizontal line behind for Orientation observation site; Experimental port, positive drug control hole add the Experimental agents intracellular signaling of different concns respectively and activating transcription factor suppresses polypeptide (the raw work synthesis in Shanghai) and positive control medicine vincristine(VCR); Blank group adds the solvent of same volume, and five multiple holes are established in every hole; Put into 37 DEG C, 5%CO
2incubator, cultivates.By 0,6,12,24,36 hours, take pictures; Measure 0,6,12,24,36h scratch width.With different time points, record the change of three fixed positions place, every hole scratch width, be cell migration distance.According to formulae discovery mobility (migration rate, MR): mobility (MR)=(testing scratch width-experiment scratch width of the 0th hour of n-th hour) × 100%/experiment scratch width of the 0th hour.As a result, suppress peptide concentration to increase with intracellular signaling and activating transcription factor, inhibition of metastasis rate declines gradually, and illustrate that intracellular signaling and activating transcription factor suppress polypeptide that breast cancer cell MCF-7 can be suppressed to move, inhibiting rate is 82.6%.
Embodiment 2
Intracellular signaling and activating transcription factor suppress polypeptide to the growth of vitro culture human breast cancer cell and survival IC50.
Adopt MTT colorimetry.By the human breast cancer cell of logarithmic growth, with 1.0 × 10
5add in 96 well culture plates, cultivate 24h, experimental port, positive drug control hole add the Experimental agents intracellular signaling of different concns respectively and activating transcription factor suppresses polypeptide (the raw work synthesis in Shanghai) and positive control medicine taxol; Blank group adds the solvent of same volume.Five multiple holes are established in every hole, cultivate 48h, respectively 0h, 2h, 8h, 14h, 20h, 24h, 36h, the every hole of 48h adds MTT, after effect 4h, add DMSO, hatch 30min, absorbance A value is measured, by formula human breast cancer cell growth inhibition ratio=(1-experimental group light absorption value/control group light absorption value) × 100% at microplate reader 620nm place.The IC50 calculating Experimental agents is 26.98 μMs.
Embodiment 3
With tumor model detection signal conduction and activating transcription factor suppress polypeptide body in vigor.
Set up MCF-7 tumor model, positive control medicine taxol; Blank group adds the solvent of same volume, and experimental group polypeptide (the raw work synthesis in Shanghai) establishes 3 dosage: 0.75,1.5,3 μMs of mg/Kg.After 21 days, observe mouse survival quantity, calculate survival rate.Result shows, and intracellular signaling and activating transcription factor suppress polypeptide effectively can protect small white mouse, and improve the survival rate of tumor-bearing mice, survival rate reaches 61.5%.
Sequence table
SEQUENCE LISTING
Pu Luoda bio tech ltd, <110> Suzhou
<120> intracellular signaling and activating transcription factor suppress polypeptide and application thereof
<130>
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 20
<212> PRT
<213> artificial sequence
<400> 1
Met Glu Gln Phe Arg His Leu Arg Ala Asn Pro Ser Trp Pro His Leu
1 5 10 15
Gln Met Phe Pro
20
Claims (2)
1. intracellular signaling and activating transcription factor suppress polypeptide, it is characterized in that its sequence is MEQFRHLRANPSWPHLQMFP.
2. intracellular signaling as claimed in claim 1 and activating transcription factor suppress the application of polypeptide in the recurrence and diversion medicaments of prevention and therapy Mammary cancer cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510157200.2A CN104725480A (en) | 2015-04-06 | 2015-04-06 | Signal transduction and transcriptional activation factor inhibitory polypeptide and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510157200.2A CN104725480A (en) | 2015-04-06 | 2015-04-06 | Signal transduction and transcriptional activation factor inhibitory polypeptide and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104725480A true CN104725480A (en) | 2015-06-24 |
Family
ID=53449954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510157200.2A Pending CN104725480A (en) | 2015-04-06 | 2015-04-06 | Signal transduction and transcriptional activation factor inhibitory polypeptide and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104725480A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101511179A (en) * | 2005-02-25 | 2009-08-19 | 密执安州立大学董事会 | Small molecule inhibitors of STAT3 and the uses thereof |
| CN101854930A (en) * | 2007-09-10 | 2010-10-06 | 波士顿生物医药公司 | A novel group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitors |
| CN102417479A (en) * | 2011-08-29 | 2012-04-18 | 南京大学 | STAT3 small molecular selective inhibitor and preparation method and application thereof |
-
2015
- 2015-04-06 CN CN201510157200.2A patent/CN104725480A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101511179A (en) * | 2005-02-25 | 2009-08-19 | 密执安州立大学董事会 | Small molecule inhibitors of STAT3 and the uses thereof |
| CN101854930A (en) * | 2007-09-10 | 2010-10-06 | 波士顿生物医药公司 | A novel group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitors |
| CN102417479A (en) * | 2011-08-29 | 2012-04-18 | 南京大学 | STAT3 small molecular selective inhibitor and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103191095A (en) | STAT (Signal Transducer And Activator Of Transcription)3 signal channel small-molecule inhibitor and application thereof | |
| CN104693280A (en) | Signal-transducer-and-activator-of-transcription suppressing polypeptide and application thereof | |
| CN104725480A (en) | Signal transduction and transcriptional activation factor inhibitory polypeptide and application thereof | |
| CN105037501A (en) | Signal transduction and activating transcription factor inhibiting polypeptide | |
| CN104693279A (en) | Signal transduction and transcription activity factor restraint polypeptide and application thereof | |
| CN104693289A (en) | Tight-junction protein inhibitor polypeptide and application thereof | |
| CN104004056B (en) | A kind of about Cyclin D protein inhibitor polypeptide and application thereof | |
| CN104725487A (en) | Tight junction protein inhibitor polypeptide and application thereof | |
| CN103739680B (en) | A kind of anti-adhesion spot kinase polypeptide and application thereof | |
| CN104725488A (en) | Tight junction protein inhibitor polypeptide and application thereof | |
| CN108175766B (en) | Application of the IMCA in preparation anti-colorectal cancer medicament | |
| CN104693281A (en) | Angiostatin activating agent polypeptide and application thereof | |
| CN105517558A (en) | Filipendula vulgaris extract and uses thereof | |
| CN103739678B (en) | Anti-adhesion spot kinase polypeptide and application thereof | |
| CN104694520A (en) | Hydrolyzed profibrinolysin polypeptide and application thereof | |
| CN104045689B (en) | A kind of about somatostatin receptor agonist polypeptide and application thereof | |
| CN104017051B (en) | A kind of Cyclin D protein inhibitor polypeptide and application thereof | |
| CN104725481A (en) | Vascular endothelial calnexin antagonist polypeptide and application thereof | |
| CN104694521A (en) | Hydrolysis plasminogen polypeptide and application thereof | |
| CN104744571A (en) | VE-cadherin (Vascular Endothelium-Cadherin) antagonist polypeptide and application thereof | |
| CN104017053B (en) | A kind of PER2 protein agonist polypeptide and application thereof | |
| CN104693283A (en) | Angiostatin activating agent polypeptide and application thereof | |
| CN104045693B (en) | A kind of about PER2 protein agonist polypeptide and application thereof | |
| CN104693282A (en) | Angiostatin activator polypeptide and application thereof | |
| CN104031128A (en) | Interleukin-33 inhibitor polypeptide and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150624 |